Lyndra Therapeutics Achieves Critical Milestones Despite COVID-19 Headwinds

Lyndra Therapeutics Achieves Critical Milestones Despite COVID-19 Headwinds

Örn Almarsson named Chief Technology Officer 

 Phase I trial for ultra-long-acting oral therapy for schizophrenia completes dosing

 28% employee growth to date in 2020 to support manufacturing and pipeline expansion 

WATERTOWN, Mass., June 10, 2020 – Lyndra Therapeutics, a clinical-stage biotech company working to make daily pills a thing of the past, achieved significant milestones in the first half of 2020 despite COVID-19 headwinds, naming Örn Almarsson as Chief Technology Officer, completing enrollment and dosing of its Phase I clinical trial for an ultra-long-acting oral risperidone therapy to treat schizophrenia, ramping up manufacturing capabilities and growing its employee base by 28%.

“The past few months show the resilience of our team, and we’ve not only stayed on course but actually built momentum toward our goal to reinvent medicines,” said Lyndra CEO Dr. Patricia Hurter. “Our first U.S. Phase I clinical trial has completed dosing, a new GMP manufacturing site has been commissioned and is now operational and manufacturing clinical materials for our first Phase 2 study, scale-up is on schedule and we’re attracting and recruiting the best in biotech, including leaders such as Örn Almarsson who have successful track records with accelerated development and commercialization.”

READ MORE: https://lyndra.com/news/lyndra-therapeutics-achieves-critical-milestones-despite-covid-19-headwinds/